$BIIB
BIOGEN INC.
Runway:cash-flow +
NasdaqMarket cap: —CIK 0000875045
Upcoming catalysts
0 surfacedNo catalysts surfaced for BIIB yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06628687 | Omaveloxolone | — | Recruiting | 2035-04-30 |
| NCT07483632 | — | Phase 3 | Not Yet Recruiting | 2034-07-28 |
| NCT07259980 | — | — | Recruiting | 2033-12-30 |
| NCT05767736 | — | — | Active Not Recruiting | 2032-12-01 |
| NCT05789758 | — | — | Recruiting | 2032-10-31 |
| NCT05658497 | — | — | Recruiting | 2032-07-06 |
| NCT05575011 | — | Phase 1 | Active Not Recruiting | 2031-11-14 |
| NCT07444489 | — | Phase 3 | Enrolling By Invitation | 2031-05-28 |
| NCT05688436 | — | — | Active Not Recruiting | 2031-01-17 |
| NCT05352919 | Litifilimab | Phase 3 | Enrolling By Invitation | 2030-03-29 |
| NCT06623890 | Omaveloxolone | — | Recruiting | 2029-10-01 |
| NCT07444450 | — | Phase 3 | Not Yet Recruiting | 2029-07-27 |
| NCT06044337 | — | Phase 3 | Enrolling By Invitation | 2029-06-26 |
| NCT06962800 | — | Phase 3 | Recruiting | 2028-12-29 |
| NCT07221669 | — | Phase 3 | Recruiting | 2028-11-28 |
| NCT07444476 | — | Phase 3 | Recruiting | 2028-06-23 |
| NCT05618379 | — | — | Active Not Recruiting | 2028-06-01 |
| NCT07219043 | — | Phase 2 | Recruiting | 2028-02-10 |
| NCT07223723 | — | Phase 4 | Recruiting | 2027-12-16 |
| NCT06953583 | Omaveloxolone | Phase 3 | Recruiting | 2027-11-16 |